METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence, urge urinary incontinence, mixed incontinence, and pelvic floor disorders by administering a SARM compound of the invention.
1 . A method of treating, preventing, suppressing or inhibiting stress urinary incontinence, urge urinary incontinence or a combination thereof in a postmenopausal female subject, comprising administering to said subject a composition comprising a SARM compound of Formula IX:
or its isomer, hydrate, pharmaceutically acceptable salt, pharmaceutical composition or any combination thereof.
2 . The method according to claim 1 , wherein said administering comprises a daily dose of 1 to 3 mg.
3 . The method according to claim 1 , wherein the administering step is up to 12 weeks.
4 . The method according to claim 2 , wherein the administering step is up to 12 weeks.
5 . The method according to claim 1 , wherein the administering step is by intermittent dosing cycles.
6 . The method according to claim 1 , wherein the administering step consists of only one dose cycle which lasts up to 12 weeks.
7 . The method according to claim 1 , wherein the subject suffers from stress urinary incontinence and urge urinary incontinence.
8 . The method according to claim 1 , wherein the composition comprises a 1 mg daily dose of said compound.
9 . The method according to claim 1 , wherein the composition comprises a 3 mg daily dose of said compound.
10 . The method according to claim 2 , wherein the duration of response following completion of the treatment is at least seven months post-treatment.
11 . The method according to claim 4 , wherein the duration of response following completion of the treatment is at least seven months post-treatment.
12 . A method of reducing the occurrence or lessening the severity of at least one of the following symptoms in a postmenopausal female subject suffering from stress urinary incontinence, urge urinary incontinence or a combination thereof: (i) average daily frequency of urination; (ii) average nightly frequency of urination; (iii) total urinary incontinence episodes; (iv) stress incontinence episodes; and (v) urinary urgency episodes; comprising administering a SARM compound of Formula IX:
or its isomer, hydrate, pharmaceutically acceptable salt, pharmaceutical composition or any combination thereof.
13 . The method according to claim 12 , wherein said administering comprises a daily dose of 1 to 3 mg.
14 . The method according to claim 12 , wherein the administering step is up to 12 weeks.
15 . The method according to claim 13 , wherein the administering step is up to 12 weeks.
16 . The method according to claim 12 , wherein the administering step is by intermittent dosing cycles.
17 . The method according to claim 12 , wherein the administering step consists of only one dose cycle which lasts up to 12 weeks.
18 . The method according to claim 12 , wherein the subject suffers from stress urinary incontinence and urge urinary incontinence.
19 . The method according to claim 12 , wherein the composition comprises a 1 mg daily dose of said compound.
20 . The method according to claim 12 , wherein the composition comprises a 3 mg daily dose of said compound.
21 . The method according to claim 13 , wherein the duration of response following completion of the treatment is at least seven months post-treatment.
22 . The method according to claim 15 , wherein the duration of response following completion of the treatment is at least seven months post-treatment.